PolyPeptide Group Intelligence Profile

polypeptide.comLast reviewed: October 20, 2026Research coverage: 83%

Overall data confidence:Unknown

Identity confidence

High

10 of 10 identity fields independently documented

Corporate continuity

Continuity supported — domain registered 1997-04-25; vendor operating under this brand/domain continuously in sources from the late 1990s (1997 supply agreement, 2010 SEC-filed supply agreement) through audited annual reports 2024–2025; site live today with current (October 2026) ad hoc announcements

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

Moderate

4 of 7 testing fields documented

Transaction transparency

Low

2 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 83%. Our research on PolyPeptide Group remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Refund policy reviewed (refund_return_policy)
Shipping policy reviewed (shipping_fulfillment_representations)
Payment methods reviewed (accepted_payment_methods)
Public summary reviewed

Overview#

PolyPeptide Group is a FIT for the directory as a U.S.-operating peptide seller/manufacturer, in the B2B CDMO category: PolyPeptide Laboratories, Inc. (a Delaware corporation, 100% subsidiary of Swiss-listed PolyPeptide Group AG, SIX: PPGN) manufactures peptide-based APIs in Torrance, CA (365 Maple Ave, 90503; 120,000 sq ft GMP site, 10+ commercial APIs) and San Diego, CA (9395 Cabot Dr, 92126), within a six-site GMP network (group revenue EUR 336.8m in 2024, EUR 389.3m in 2025; ~1,395–1,469 FTE). Transparency is at the top of the directory's range: audited annual reports name the parent incorporation (2021-04-06, Zug, CHE-159.266.771), the full subsidiary table, the board and the executive committee (CEO Juan José González). All defined regulatory searches returned No Record Found in the defined search — FDA warning letters, recalls, import alerts, FTC, state AG, criminal/injunctive — with routine FDA GMP inspections (incl. a Torrance Form 483, 2024-05-10) explicitly NOT counted as enforcement. The only civil matter found is an employment class action (Huynh, BC680872). Testing fields reflect the B2B model: no public COAs, portals or lot documents exist (certificates are customer-confidential under master supply agreements), so batch specificity, independent lab identity and test recency are honestly Unknown, while payment, refund and shipping fields are likewise Unknown because terms live in B2B contracts — the Annual Report confirms all customer revenue is business-to-business. Gaps requiring a live SoS session: U.S. entity status, U.S. formation date and registered agent (CA bizfile detail / Delaware record not retrieved via text fetch; Delaware incorporation itself is corroborated by a Tier 1 CA Treasurer report and an SEC-filed contract). The one material forward event is the pending Samsung Biologics tender offer (87.92% tendered at definitive interim, 2026-10-16; completion expected late 2026 / Q1 2027) — a change-of-control to track, not a risk flag. No High/Critical severity findings.

Company Identity#

Vendor Brand NamePolyPeptide Group

HighSource: PolyPeptide — Company page (CDMO for peptide-based therapies; since 1952; over 1,000 peptides in GMP quality)

Primary Website Domainpolypeptide.com

ModerateSource: PolyPeptide Group — official website (intake domain confirmation)

Legal Entity NamePolyPeptide Laboratories, Inc. (U.S. operating entity); parent: PolyPeptide Group AG

HighSource: PolyPeptide Annual Report 2024 — Corporate Governance Report (parent incorporated 2021-04-06, CHE-159.266.771, Neuhofstrasse 24, 6340 Baar; subsidiary table; Executive Committee)

State of RegistrationDelaware (U.S. entity PolyPeptide Laboratories, Inc.); parent PolyPeptide Group AG incorporated in Switzerland (Canton of Zug)

HighSource: Commercial Supply Agreement for Linaclotide (SEC-filed, Justia) — 'PolyPeptide Laboratories Inc., a Delaware corporation with its principal offices at 365 Maple Avenue, Torrance, CA 90503' (agreement dated 2010-06-23)

Entity StatusActive — California foreign corporation #1996388, good standing (SOS, FTB, Agent, VCFCF) as of 2026-10-20

HighSource: California Secretary of State bizfile — POLYPEPTIDE LABORATORIES INC. entity #1996388

Incorporation / Formation Date1996-12-20 (California registration filing date; Delaware corporation)

ModerateSource: California Secretary of State bizfile — POLYPEPTIDE LABORATORIES INC. entity #1996388

Named Principals / ManagersGroup Executive Committee (Annual Report 2024, as of 2024-12-31): Juan José González — CEO (appointed 2023); Marc Augustin — CFO (appointed 2024); Christina Del Vecchio — General Counsel / Chief Legal Officer; Jens Fricke — Director Global Operations. Board Chair: Peter Wilden. Current officers of the U.S. subsidiary itself are not named in the sources retrieved.

ModerateSource: PolyPeptide Annual Report 2024 — Corporate Governance Report (parent incorporated 2021-04-06, CHE-159.266.771, Neuhofstrasse 24, 6340 Baar; subsidiary table; Executive Committee)

Registered AgentUlrika Camilla Andren Ny — 365 Maple Avenue, Torrance, CA 90503

HighSource: California Secretary of State bizfile — POLYPEPTIDE LABORATORIES INC. entity #1996388

Operating Address365 Maple Avenue, Torrance, CA 90503, USA (principal U.S. address, PolyPeptide Laboratories, Inc.); additional U.S. site: 9395 Cabot Drive, San Diego, CA 92126, USA; group headquarters: Neuhofstrasse 24, 6340 Baar, Switzerland

HighSource: U.S. EPA Envirofacts P2 Search — POLYPEPTIDE LABORATORIES INC., 365 MAPLE AVE, TORRANCE, CA 90503, Facility ID 9050WPLYPP365MA, Pharmaceutical Preparation Manufacturing (325412)

Address ConsistencyConsistent — Torrance 365 Maple Ave, Torrance, CA 90503 is identical across vendor, .gov (EPA, CA DIR) and SEC-filed contract sources spanning 2010–2026; San Diego 9395 Cabot Dr is likewise consistent; headquarters Neuhofstrasse 24, Baar is consistent across annual reports, press releases and LinkedIn

HighSource: U.S. EPA Envirofacts P2 Search — POLYPEPTIDE LABORATORIES INC., 365 MAPLE AVE, TORRANCE, CA 90503, Facility ID 9050WPLYPP365MA, Pharmaceutical Preparation Manufacturing (325412)

Domain and Digital Identity#

Domain Registration Date1997-04-25

HighSource: Verisign RDAP — polypeptide.com

Domain Ownership / Registrar Change HistoryPartially known — current registrar CSC Corporate Domains, Inc. (IANA Registrar ID 299); RDAP record last changed 2026-04-22; registrant identity is not disclosed in RDAP (corporate registrar, no registrant name published)

LowSource: Verisign RDAP — polypeptide.com

Website ContinuityContinuity supported — domain registered 1997-04-25; vendor operating under this brand/domain continuously in sources from the late 1990s (1997 supply agreement, 2010 SEC-filed supply agreement) through audited annual reports 2024–2025; site live today with current (October 2026) ad hoc announcements

ModerateSource: Verisign RDAP — polypeptide.com

Contact Channel IntegrityPublished channels are consistent: group media mediateam@polypeptide.com and investor relations investorrelations@polypeptide.com, group phone +41 43 502 0580 (Baar); U.S. Torrance phone +1 310-782-3569, toll-free +1 800 770 0557, fax +1 310-782-3645 (vendor SDS). No conflicting contact details found

ModerateSource: PolyPeptide Laboratories Safety Data Sheet PPL-1190 (Liraglutide), rev. 2017-04-26, hosted on polypeptide.com — 365 Maple Avenue, Torrance, CA 90503; Tel +1 310-782-3569; Toll Free +1 800 770 0557; Fax +1 310-782-3645

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

HighSource: Defined web search of fda.gov warning letters — no letter naming PolyPeptide Group / PolyPeptide Laboratories

FDA Recall / Safety Action HistoryNo Record Found in the defined search

ModerateSource: Defined web search — PolyPeptide Laboratories recall / import alert / attorney general / criminal / injunction

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search — PolyPeptide Laboratories recall / import alert / attorney general / criminal / injunction

FTC Enforcement HistoryNo Record Found in the defined search

HighSource: Defined web search of ftc.gov — no action naming PolyPeptide Group / PolyPeptide Laboratories (hits were generic scientific uses of the word 'polypeptide')

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search — PolyPeptide Laboratories recall / import alert / attorney general / criminal / injunction

Relevant Civil LitigationLimited record found — employment class action only: Huynh v. Polypeptide Laboratories, Inc., Case No. BC680872, California Superior Court, County of Los Angeles (listed in class counsel's declaration among wage-and-hour / employment class actions handled; merits and outcome not established in the source retrieved)

LowSource: Class counsel declaration (California Superior Court filing) listing 'Huynh v. Polypeptide Laboratories, Inc., Case No. BC680872, California Superior Court, County of Los Angeles' among class-action cases handled

Criminal / Injunctive ProceedingsNo Record Found in the defined search

ModerateSource: Defined web search — PolyPeptide Laboratories recall / import alert / attorney general / criminal / injunction

Testing and COA Evidence#

Public COA AvailabilityNo public COAs posted — no COA library, portal or per-product certificate posting exists on the vendor's public site; testing is B2B GMP release testing for contract customers (Torrance has a QC lab supporting development and commercial activities), with certificates issued to the customer under contract, not published for retail buyers

ModerateSource: PolyPeptide — San Diego & Torrance, USA manufacturing sites page (Torrance 120,000 sq ft GMP facility; San Diego 45,000 sq ft; both FDA-inspected multiple times)

Batch / Lot SpecificityNot independently verified

UnknownSource: PolyPeptide — San Diego & Torrance, USA manufacturing sites page (Torrance 120,000 sq ft GMP facility; San Diego 45,000 sq ft; both FDA-inspected multiple times)

Independent Laboratory IdentityNot independently verified

UnknownSource: PolyPeptide — San Diego & Torrance, USA manufacturing sites page (Torrance 120,000 sq ft GMP facility; San Diego 45,000 sq ft; both FDA-inspected multiple times)

COA Verification StatusNot verifiable through a public portal — the vendor offers no COA lookup/verification system (B2B certificates are customer-confidential under supply contracts)

ModerateSource: PolyPeptide — Company page (CDMO for peptide-based therapies; since 1952; over 1,000 peptides in GMP quality)

Test RecencyNot independently verified

UnknownSource: Redica Systems investigator profile — 'Polypeptide Laboratories, Inc. - Form 483, 2024-05-10' (routine inspection record)

Testing CoverageVendor-stated coverage is program-wide under GMP: over 1,000 peptides manufactured in GMP quality since 1952; six GMP-certified facilities; Torrance QC lab supports development and commercial activities and the site holds approvals for over 10 commercial APIs; San Diego manufactures GMP peptides for clinical use plus research-grade peptides (mg–g)

ModerateSource: PolyPeptide — Company page (CDMO for peptide-based therapies; since 1952; over 1,000 peptides in GMP quality)

Evidence ConsistencyConsistent — identity, addresses, GMP status and business model agree across audited annual reports, the vendor site, .gov facility records and SEC-filed contracts over a 1997–2026 span. Apparent date tension is explained, not contradictory, in the annual report: operating roots 1952 (Malmö), independence 1996, and the current Swiss holding company PolyPeptide Group AG incorporated 2021-04-06 for the IPO

ModerateSource: PolyPeptide Annual Report 2024 — Corporate Governance Report (parent incorporated 2021-04-06, CHE-159.266.771, Neuhofstrasse 24, 6340 Baar; subsidiary table; Executive Committee)

Payment, Refund and Shipping#

Accepted Payment MethodsNot independently verified

UnknownSource: PolyPeptide Annual Report 2025 (revenue EUR 389,327k in 2025 / EUR 336,792k in 2024; 'All revenues from contracts with customers classify as business-to-business'; Commercial revenue under master supply agreements / work / purchase orders)

Refund / Return PolicyNot independently verified

Shipping & Fulfillment RepresentationsNot independently verified

UnknownSource: PolyPeptide — Company page (CDMO for peptide-based therapies; since 1952; over 1,000 peptides in GMP quality)

Terms / Policy StabilityNo public retail terms exist to diff — commercial terms have been consistently framed as negotiated B2B master supply / work-order terms in annual reports 2024 and 2025; intake pass, so no policy-page change history is claimed

LowSource: PolyPeptide Annual Report 2024 — Corporate Governance Report (parent incorporated 2021-04-06, CHE-159.266.771, Neuhofstrasse 24, 6340 Baar; subsidiary table; Executive Committee)

Customer Complaint PatternNo Record Found in the defined search

ModerateSource: Defined web search — PolyPeptide Laboratories recall / import alert / attorney general / criminal / injunction

Material Changes#

No material changes recorded.

Sources#

California State Treasurer / CAEATFA staff report 2017-09-19 — 'PolyPeptide Laboratories, Inc. (or Applicant), a Delaware corporation, is a part of the PolyPeptide Group. PolyPeptide manufactures pharmaceutical peptides on contract'Tier 1 · AuthoritativeRegulatory SearchAuthoritative

Retrieved: October 20, 2026